Translating Biomarkers into Clinical Strategy: Lessons from Other Immunological Diseases for IBD

• Discuss Precision Medicine opportunities for in IBD using predictive and prognostic biomarkers, drawing parallels with immunology and Oncology programs advancing into later trials
• Unpack the gap between translational biomarker insights and real-world diagnostics, including regulatory, commercial, and scalability hurdlesDiscuss challenges in moving from translation level biomarker insights to clinically validated tools

Speakers:

Neeraj Adya

Immunology & Diagnostic Development Leader

Johnson & Johnson